History & Overview Annual Report President's Pages Center News Community Affairs

Make a Gift Yankees Universe Fund Fred's Team Thomas Blake Sr. Memorial Research Fund Donating Blood & Platelets Volunteering Thrift Shop Park Avenue Potluck Cookbook

Press Releases Information for Journalists News@MSKCC

Manhattan New Jersey Long Island Westchester

Working at Memorial Sloan-Kettering Work Sites College Recruitment About Nursing Job Fairs & Career Days Job Search & Apply Online

Clinical Trials

Clicking a link below will scroll the
page down to the relevant section

Aplastic Anemia
Hematologic Disorders
Hematologic Malignancies
Multiple Myeloma
Myelodysplastic Syndrome

Aplastic Anemia

A Phase II Pilot Trial of Hematopoietic Stem Cell Transplantation with Total Body Irradiation, Cyclophosphamide & Fludarabine to Treat Patients with Fanconi Anemia Lacking a Genotypically Identical Donor
Boulad, Farid, MD

[Protocol 01-062]

Hematologic Disorders

A Phase II Study of Melphalan with Stem Cell Transplant and Adjuvant Bortezomib and Dexamethasone for Recently Diagnosed Untreated Systemic Light-Chain Amyloidosis
Comenzo, Raymond, MD

[Protocol 07-006]
A Pilot Trial to Assess the Feasibility and Safety of G-CSF Mobilization of Hematopoietic Stem Cells in Patients with Beta-thalassemia Major
Boulad, Farid, MD

[Protocol 08-030]
Phase I/II Study of VELCADE^® (Bortezomib) to Treat Patients with Light-Chain Amyloidosis
Comenzo, Raymond, MD

[Protocol 05-069]

Hematologic Malignancies

A Phase I Study of the Safety and Pharmacokinetics of the Proteasome Inhibitor PR-171 in Patients with Hematological Cancers
Comenzo, Raymond, MD

[Protocol 05-137]
Genetic Variability as a Determinant of Chemotherapy Toxicity and Response in Pediatric Cancer and Bone Marrow Transplantation Patients
Meyers, Paul, MD

[Protocol 03-123]

Multiple Myeloma

A Phase I Study of the Safety and Pharmacokinetics of the Proteasome Inhibitor PR-171 in Patients with Hematological Cancers
Comenzo, Raymond, MD

[Protocol 05-137]
A Phase II Clinical Trial of Bortezomib, Pegylated Liposomal Doxorubicin (DOXIL^®), and Dexamethasone Followed by Thalidomide and Dexamethasone with or without Bortezomib in Patients with High-Risk or Resistant Multiple Myeloma
Comenzo, Raymond, MD

[Protocol 06-067]
A Phase II Study of Lenalidomide and Rituximab for Patients with Relapsed and/or Refractory CD20+ Multiple Myeloma
Cohen, Adam, MD

[Protocol 07-070]
A Phase III Study of Maintenance Therapy with CC-5013 or Placebo After Autologous Stem Cell Transplantation for Multiple Myeloma
Hassoun, Hani, MD

[Protocol 05-080]
A Phase III Trial of Zoledronic Acid with and without Thalidomide in Patients with Early-Stage Multiple Myeloma
Hassoun, Hani, MD

[Protocol 06-015]
A Study Evaluating the Effectiveness of Leuprolide for Enhancing Immune Function After Autologous Stem Cell Transplantation
Cohen, Adam, MD

[Protocol 07-046]
Phase III Study of Three Treatment Regimens in Patients with Previously Untreated Multiple Myeloma Who Are Not Candidates for High-Dose Chemotherapy and Autologous Stem Cell Transplantation
Hassoun, Hani, MD

[Protocol 08-018]

Myelodysplastic Syndrome

A Phase I Combination Trial of SGN-33 (Anti-huCD33 mAb; HuM195; Lintuzumab) and Lenalidomide (Revlimid^®) in Patients with Myelodysplastic Syndromes
Jurcic, Joseph, MD

[Protocol 07-143]
A Phase I Study of CYT 107 in Recipients of HLA-Matched T Cell-Depleted Peripheral Blood Stem Cell or Bone Marrow Transplants
Van Den Brink, Marcel, MD, PhD

[Protocol 07-127]
A Phase I Study of SGN-33 (Lintuzumab) in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome
Jurcic, Joseph, MD

[Protocol 05-132]
A Phase I Study of WT1-Sensitized T cells for Residual or Relapsed Leukemia after Allogeneic Hematopoietic Progenitor Cell Transplantation
O'Reilly, Richard, MD

[Protocol 07-055]
A Phase I/II Study of Decitabine and All-Trans Retinoic Acid (Tretinoin) for Patients with Myelodysplastic Syndromes
Klimek, Virginia, MD

[Protocol 06-054]
A Phase I/II Trial of Clofarabine, Melphalan, and Thiotepa Followed by an Allogeneic Stem Cell Transplant for the Treatment of High-Risk and/or Advanced Hematologic Malignancies
Boulad, Farid, MD

[Protocol 06-125]
A Phase II Multicenter Trial of Myeloablative Double Unit Umbilical Cord Blood Transplantation in Adults with Hematological Cancers
Barker, Juliet, MBBS

[Protocol 07-072]
A Phase II Pilot Trial of Hematopoietic Stem Cell Transplantation with Total Body Irradiation, Cyclophosphamide & Fludarabine to Treat Patients with Fanconi Anemia Lacking a Genotypically Identical Donor
Boulad, Farid, MD

[Protocol 01-062]
A Phase II Study of Peri-transplant Palifermin followed by an Allogeneic T-Cell-Depleted Stem Cell Transplant in Patients with Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Evolved from MDS
Castro-Malaspina, Hugo, MD

[Protocol 08-008]
A Phase II Trial of Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplants after a Myeloablative Preparative Regimen for Adult Patients with Lymphohematopoietic Disorders
Jakubowski, Ann, MD, PhD

[Protocol 01-070]
A Phase II Trial of HLA Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Leukemia Following Allogeneic Hematopoietic Stem Cell Transplant
Hsu, Katharine, MD, PhD

[Protocol 07-035]
A Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients with Thoracic and Myeloid Neoplasms
Krug, Lee, MD

[Protocol 06-085]
A Study to Evaluate the Safety and Efficacy of AMG 531 in Thrombocytopenic Patients with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Klimek, Virginia, MD

[Protocol 06-115]
Cyclophosphamide, Fludarabine, and Total Body Irradiation Followed by the Transplantation of Unrelated Double-Unit Donor Umbilical Cord Blood Grafts for Patients with Hematological Malignancy
Barker, Juliet, MBBS

[Protocol 06-014]
Structural Imaging and Cognitive Functions in Adult Stem Cell Transplant Recipients Treated with Radiation Therapy and Chemotherapy
Correa, Denise, PhD

[Protocol 06-162]

Site Map \| Index	Legal Disclaimer \| Privacy Practices \| Public Notices

©2008 Memorial Sloan-Kettering Cancer Center. 212-639-2000 1275 York Avenue New York, NY 10065.	PublicAffairs@mskcc.org